Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Celgene

Status: Completed

Conditions: Lymphoma Nonhodgkin

Study type: Observational

Funder types: Industry

Identifiers

NCT04618081

U1111-1260-3127 (Registry Identifier)

CC-5013-TCL-003

Details and patient eligibility

About

To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called.

1. Planned registration period 1.5 years
2. Planned surveillance period 3 years from the start of this survey

Enrollment: 151 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma

Exclusion criteria

• N/A

Trial design

151 participants in 1 patient group

Participants with FL or MZL

Description:

Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.